ReviewPsychopharmacology2025
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.
Review in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Novel Tetrahydropyridinyl-6,6-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Novel 6,5-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Novel 5,6-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.ACS chemical neuroscience · 2026Review
- Novel Tricyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.ACS medicinal chemistry letters · 2026Article
- Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders.ACS medicinal chemistry letters · 2026Article
- Doped CScientific reports · 2025Article
- Novel Heterocyclic Compounds as 5‑HT2C Agonists for Treating Depression, Drug Addiction, Alcoholism, PTSD and Neuropathic Pain.ACS medicinal chemistry letters · 2025Article
- Novel Compounds as 5‑HT2A Agonists for Treating Mental Illness or CNS Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Compounds as 5‑HT2A Agonists for Treating Mental Illness or CNS Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Phenethylamines as 5‑HT2A Agonists for Treating Depression, Drug Addiction, Alcoholism, PTSD, and Neuropathic Pain.ACS medicinal chemistry letters · 2025Article
- Novel Benzofuran and Benzothiophene Psychedelic Psychoplastogens as 5‑HT2C Agonists for Treating Neurological Diseases.ACS medicinal chemistry letters · 2025Article
- Novel Indazole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Phenoxy and Benzyloxy Substituted Psychedelic Psychoplastogens as 5‑HT2C Agonists for Treating Neurological Diseases.ACS medicinal chemistry letters · 2025Article
- Novel Tricyclic Psychedelic Psychoplastogens as 5‑HT2C Agonists for Treating Neurological Diseases.ACS medicinal chemistry letters · 2025Article
- Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.ACS medicinal chemistry letters · 2025Article
- Novel N‑Substituted Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric Disorders.ACS medicinal chemistry letters · 2025Article
- Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain Disorders.ACS medicinal chemistry letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleN, N-Dimethyltryptamine (DMT), a potent serotonergic psychedelic, bridges ancient wisdom and modern science. The mechanisms underlying its powerful psychedelic effects and out-of-body experiences continue to intrigue scientists. The functional role of DMT remains ambiguous. This paper explores the endogenous presence of DMT in the human body and its diverse neuroregulatory functions, which influence hierarchical brain connectivity, and the mechanisms driving its psychedelic effects.
objectiveThis paper aims to analyze DMT-receptor binding, its effects on neuronal modulation, brain oscillations, and connectivity, and its influence on hallucinations, out-of-body experiences, and cognitive functions.
resultsDMT administration induces significant changes in brain wave dynamics, including reduced alpha power, increased delta power, and heightened Lempel-Ziv complexity, reflecting enhanced neural signal diversity. Functional neuroimaging studies reveal that DMT enhances global functional connectivity (GFC), particularly in transmodal association cortices such as the salience network, frontoparietal network, and default mode network, correlating with ego dissolution. The receptor density-dependent effects of DMT were mapped to brain regions rich in serotonin 5-HT2A receptors, supporting its role in modulating consciousness and neuroplasticity.
conclusionThis integrated analysis provides insights into the profound effects of DMT on human cognition, and consciousness, and its role in enhancing natural well-being. As we uncover the endogenous functions of DMT, it becomes clear that the study of its biology reveals a complex interplay between brain chemistry and consciousness.
Indexed as
Identifiers
40210737What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.